Biosimilars: FDA’s Four-Tiered Assessment Draws Industry Scrutiny
This article was originally published in PharmAsia News
Executive Summary
PhRMA asks FDA to remove the categorization of a product as not similar, similar, highly similar, or similar with fingerprint-like similarity.